Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


High-density lipoprotein: what is the best way to measure its antiatherogenic potential?

Remaley AT, Warnick GR.

Expert Opin Med Diagn. 2008 Jul;2(7):773-88. doi: 10.1517/17530059.2.7.773.


Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.

Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman AM, Reddy ST.

Diabetes. 2010 Dec;59(12):3223-8. doi: 10.2337/db10-0844. Epub 2010 Sep 8.


ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta.

Vaziri ND, Bai Y, Yuan J, Said HL, Sigala W, Ni Z.

Am J Nephrol. 2010;32(3):201-11. doi: 10.1159/000316479. Epub 2010 Jul 16.


Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway.

Yao X, Fredriksson K, Yu ZX, Xu X, Raghavachari N, Keeran KJ, Zywicke GJ, Kwak M, Amar MJ, Remaley AT, Levine SJ.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1228-38. doi: 10.1164/rccm.201002-0308OC. Epub 2010 Jul 9.


Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke.

Lapergue B, Moreno JA, Dang BQ, Coutard M, Delbosc S, Raphaeli G, Auge N, Klein I, Mazighi M, Michel JB, Amarenco P, Meilhac O.

Stroke. 2010 Jul;41(7):1536-42. doi: 10.1161/STROKEAHA.110.581512. Epub 2010 Jun 3.


Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

D'Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, Moore XL, Chin-Dusting J, Remaley AT, Sviridov D.

Circ Res. 2010 Jul 23;107(2):217-27. doi: 10.1161/CIRCRESAHA.110.216507. Epub 2010 May 27.


The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats.

Dai L, Datta G, Zhang Z, Gupta H, Patel R, Honavar J, Modi S, Wyss JM, Palgunachari M, Anantharamaiah GM, White CR.

J Lipid Res. 2010 Sep;51(9):2695-705. doi: 10.1194/jlr.M008086. Epub 2010 May 22.


ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation.

Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR.

Science. 2010 Jun 25;328(5986):1689-93. doi: 10.1126/science.1189731. Epub 2010 May 20.


5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT.

J Pharmacol Exp Ther. 2010 Aug;334(2):634-41. doi: 10.1124/jpet.110.167890. Epub 2010 May 19.


Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.

Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY, Park CS.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):633-42. doi: 10.1164/rccm.200905-0659OC. Epub 2010 May 12.


Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.

Yetukuri L, Söderlund S, Koivuniemi A, Seppänen-Laakso T, Niemelä PS, Hyvönen M, Taskinen MR, Vattulainen I, Jauhiainen M, Oresic M.

J Lipid Res. 2010 Aug;51(8):2341-51. doi: 10.1194/jlr.M006494. Epub 2010 Apr 29.


ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis.

Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR.

Circ Res. 2010 Jun 25;106(12):1861-9. doi: 10.1161/CIRCRESAHA.110.217281. Epub 2010 Apr 29.


Biological properties of apolipoprotein a-I mimetic peptides.

Getz GS, Wool GD, Reardon CA.

Curr Atheroscler Rep. 2010 Mar;12(2):96-104. doi: 10.1007/s11883-010-0097-4. Review.


ApoE mimetic peptide decreases Abeta production in vitro and in vivo.

Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, Davis GC, Dakshanamurthy S, Turner RS, Pak DTs, Rebeck GW, Paige M, Hoe HS.

Mol Neurodegener. 2010 Apr 20;5:16. doi: 10.1186/1750-1326-5-16.


High density lipoprotein structure-function and role in reverse cholesterol transport.

Lund-Katz S, Phillips MC.

Subcell Biochem. 2010;51:183-227. doi: 10.1007/978-90-481-8622-8_7. Review.


Niacin: from mechanisms of action to therapeutic uses.

Al-Mohaissen MA, Pun SC, Frohlich JJ.

Mini Rev Med Chem. 2010 Mar;10(3):204-17. Review.


A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.

Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S.

J Lipid Res. 2010 Jun;51(6):1496-503. doi: 10.1194/jlr.M003665. Epub 2010 Jan 14.


L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.

Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, Fogelman AM.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):283-9. doi: 10.1161/ATVBAHA.109.200162. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):e174. Dosage error in article text.


The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):246-52. doi: 10.1161/ATVBAHA.109.200196. Epub 2009 Dec 3.

Supplemental Content

Support Center